Core Insights - Doximity, Inc. (NYSE:DOCS) is recognized as one of the 10 Best New AI Stocks to Buy, with a Buy rating and a price target of $31 set by Freedom Capital analyst Gene Mannheimer, who highlights the company's strong network effects and scalable business model [1] - Piper Sandler has raised its price target on Doximity to $42 from $40 while maintaining an Overweight rating, emphasizing the strength of Doximity's AI tool suite, particularly DoxGPT, which enhances user engagement and competitive positioning in digital healthcare [3] - Doximity operates a leading digital platform for medical professionals in the U.S., combining professional networking with AI-powered clinical tools, which positions the company for sustained growth amid increasing AI adoption in healthcare [4] Company Overview - Doximity's offerings help physicians streamline workflows and access high-quality medical information, benefiting from strong network effects that drive user retention [4] - The company's recent share price weakness is viewed as an attractive entry point, suggesting that the market may be underestimating its long-term earnings potential [1]

Core Viewpoint - Piper Sandler has raised its price target on Doximity Inc. to $42 from $40 while maintaining an Overweight rating, indicating a positive outlook on the company's stock performance [1] Group 1: Doximity's AI Tool Suite - Insights from a demonstration led by CEO Jeff Tangney highlighted the strengths of Doximity's AI tool suite, particularly DoxGPT, which is noted for its integration within the Doximity ecosystem, the quality and accuracy of clinical reference responses, and a strong evidence base supporting its medical AI capabilities [2] - A new feature called PeerCheck allows healthcare professionals to efficiently transition from clinical questions to citations and original sources, enhancing the utility of DoxGPT [2] Group 2: Market Potential and Stock Valuation - As AI tools like Scribe and DoxGPT become integrated into Doximity's workflow platform, there is an expectation of increased adoption among individual healthcare professionals and enterprise contracts with hospitals and health systems, creating a virtuous cycle [3] - Piper Sandler believes the market is undervaluing DoxGPT's potential, especially following the fiscal third-quarter 2026 EPS results, leading to an updated price target of $42 based on a 20.0x multiple applied to slightly higher calendar 2027 adjusted EBITDA estimates [4]

Unity Software - Unity Software, founded in 2004 and based in San Francisco, provides a software platform for creating and expanding video games across various platforms, including mobile, PC, console, and XR [3] - The company has a market capitalization of approximately $8 billion and has seen its stock decline by 58% year to date [8] - Unity's revenue outlook for Q1 2026 is projected to be between $480 million and $490 million, which is below the Wall Street expectation of $494 million [9] - In Q4 2025, Unity reported a revenue of $503 million, a 10% year-over-year increase, and exceeded forecasts by $10.18 million [10] - Analyst Martin Yang from Oppenheimer maintains a positive outlook on Unity, suggesting that the recent stock sell-off is misplaced and that the company will see accelerating revenue growth and margin expansion in 2026 [11] - The consensus rating for Unity is Moderate Buy, with 15 Buy, 4 Hold, and 1 Sell ratings, and an average target price of $37.53 indicating a potential upside of 102% [12] Thomson Reuters - Thomson Reuters, formed in 2008, is a global information and content conglomerate with a market cap of nearly $37 billion, providing services to professionals in legal, tax, accounting, and compliance fields [13] - The company reported $2 billion in revenue for Q4 2025, a nearly 5% year-over-year increase, and exceeded estimates by $9.5 million [16] - Analyst Drew McReynolds from RBC views the current stock price as an opportunity for investors, projecting a 12-month price target of $126, which implies a 47% gain [17] - The consensus rating for Thomson Reuters is Strong Buy, with 10 Buy and 3 Hold ratings, and an average target price of $134.59 indicating a potential gain of 57% [17] Doximity - Doximity is a health-tech platform designed for medical professionals, connecting approximately 80% of US doctors and 50% of nurse practitioners [20] - The company reported $185.1 million in revenue for fiscal Q3 2026, a 10% year-over-year increase, and exceeded forecasts by $3.5 million [23] - Doximity's shares have declined by 42.5% this year, primarily due to low guidance for fiscal Q4 2026, projecting revenue between $143 million and $144 million compared to a consensus of $150.53 million [22] - Analyst Richard Close from Canaccord believes the recent sell-off is an overreaction and maintains a Buy rating with a price target of $34, predicting a 34% upside [24] - The consensus rating for Doximity is Strong Buy, with 14 Buy and 4 Hold ratings, and an average target price of $41.47 indicating a potential upside of 63% [24]

Core Insights - Doximity, Inc. reported adjusted earnings per share (EPS) of 46 cents for Q3 fiscal 2026, a 2.2% increase year over year, exceeding the Zacks Consensus Estimate by 4.5% [2] - The company's revenues for the quarter reached $185.1 million, marking a 10% year-over-year growth and surpassing the Zacks Consensus Estimate by 2.3% [3] Financial Performance - Subscription revenues amounted to $175.4 million, up 8.1% year over year, driven by a 112% net revenue retention rate and growth in large accounts [4] - Other revenues increased significantly by 52.6% year over year to $9.7 million [4] - Gross profit rose 7.7% year over year to $166.4 million, but gross margin contracted by 170 basis points to 89.9% [5] - Operating profit totaled $71.9 million, reflecting a 10% decline from the prior year, with operating margin contracting 855 basis points to 38.9% [6] Cash Position - Doximity ended Q3 fiscal 2026 with cash and cash equivalents of $64.8 million, down from $169.2 million at the end of Q2 [7] - Cumulative net cash provided by operating activities was $216.9 million, compared to $174.8 million a year ago [7] Guidance - For Q4 fiscal 2026, Doximity expects revenues between $143 million and $144 million, below the Zacks Consensus Estimate of $149.8 million [10] - The full fiscal year revenue outlook has been narrowed to between $642.5 million and $643.5 million, compared to the previous range of $640 million to $646 million, also below the consensus estimate of $645.3 million [10] Growth Drivers - Doximity experienced strong platform momentum with 3 million registered members, reaching over 85% of U.S. physicians [12] - Engagement metrics showed record highs, with significant increases in active users and workflow solutions [13] - AI adoption was a key growth driver, with over 300,000 prescribers using Doximity's AI tools during the quarter [14]

Core Viewpoint - Doximity Inc. is considered an oversold stock with potential for investment, supported by recent upgrades from Morgan Stanley and Barclays, highlighting strong user engagement and conservative estimates as attractive entry points for investors [1][2][3]. Group 1: Analyst Upgrades - Morgan Stanley upgraded Doximity from Equal Weight to Overweight with a price target increase from $62 to $65, citing the stock's underperformance as inconsistent with business checks and growing user engagement [1]. - Barclays initiated coverage of Doximity with an Overweight rating and a price target of $63, while maintaining a Neutral stance on the broader US healthcare tech sector [2]. Group 2: User Engagement and AI Integration - Doximity's strategic focus on AI has led to significant user engagement, with AI Scribe users nearly tripling from FQ1 2026 to FQ2 2026 [3]. - The integration of Pathway's medical data sets and AI models into the DoxGPT feature has provided physicians access to over 2,000 medical journals and drug references, contributing to a 50% quarter-over-quarter increase in AI-related Quality Adjusted Users (QAUs) [3]. Group 3: Company Overview - Doximity operates as a digital platform for medical professionals in the US, with potential as an investment, although some analysts suggest other AI stocks may offer greater upside potential [4].

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a technology-driven digital health platform that provides personalized care through software, data, and virtual clinical workflows [1][2] - The company has launched new services, including Labs for biomarker tracking and expanded offerings in menopause and men's health [2][7] - Recent acquisitions, including Livewell and YourBio Health, enhance HIMS' diagnostic capabilities and geographic reach [3][7] Company Developments - Hims & Hers has introduced Labs, allowing customers to monitor biomarkers and receive personalized action plans from doctors [2][7] - The company has expanded into menopause care and launched branded testosterone treatments with at-home testing options [2][7] - The acquisition of Livewell marks HIMS' entry into Canada, while YourBio Health integrates blood-sampling technology into its platform [3][7] Financial Performance - Hims & Hers shares have increased by 56.7% year to date, outperforming the industry growth of 8.1% [6] - The forward 12-month price-to-sales ratio for HIMS is 3.2X, lower than the industry average of 4.9X but higher than its three-year median of 2.6X [9] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates a 77.8% improvement from 2024 [9]

Core Insights - Hims & Hers Health, Inc. operates as a connected healthcare platform, linking consumers with licensed clinicians, diagnostics, and pharmaceutical partners, focusing on coordinated care rather than isolated transactions [1][3] Company Developments - Recent launches include a new Labs offering for whole-body diagnostic testing, providing customers with biomarker insights and clinician-developed action plans [2] - The menopause specialty connects women to hormonal health providers, expanding treatment options with ongoing clinical oversight [2] - Innovative testosterone treatments for men, supported by at-home testing and provider review, illustrate the integration of pharmaceutical collaboration, diagnostics, and personalized care [2][7] Market Performance - Hims & Hers shares have gained 39.1% year to date, outperforming the industry growth of 9.4% [6] - The forward 12-month price-to-sales ratio for Hims & Hers is 2.8X, lower than the industry average of 5.1X but higher than its three-year median of 2.6X [9] Earnings Estimates - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share suggests a 77.8% improvement from 2024 [9] - Current quarter EPS estimate is 0.04, with a projected increase to 0.14 next quarter [10]

Core Insights - Doximity, Inc. reported adjusted earnings per share (EPS) of 45 cents for Q2 fiscal 2026, a 50% increase year over year, exceeding the Zacks Consensus Estimate by 18.4% [1][8] - The company's revenues reached $168.5 million in Q2, reflecting a year-over-year growth of 23.2% and surpassing the Zacks Consensus Estimate by 6.8% [2][8] Revenue Breakdown - Subscription revenues amounted to $159.5 million, up 23% year over year, driven by increased spending from existing customers and a net revenue retention rate of 118% [3] - Other revenues totaled $9.1 million, marking a 25.9% increase year over year [3] Margin Analysis - Gross profit increased by 23.5% year over year to $152.1 million, with a gross margin expansion of 30 basis points to 90.3% [4][8] - Operating profit was $63.7 million, a 19.8% increase from the prior year, although the operating margin contracted by 100 basis points to 37.8% [5][8] Financial Position - Doximity ended Q2 fiscal 2026 with cash and cash equivalents of $169.2 million, up from $137.3 million at the end of Q1 [6] - Cumulative net cash from operating activities was $156 million, compared to $109.6 million a year ago [6] Future Guidance - For Q3 fiscal 2026, Doximity expects revenues between $180 million and $181 million, exceeding the Zacks Consensus Estimate of $178.2 million [7] - The full fiscal year revenue outlook has been raised to between $640 million and $646 million, up from the previous estimate of $628 million to $636 million [9] Product and Engagement Highlights - The company introduced multiple product updates focused on AI and workflow expansion, including the integration of Pathway's medical dataset into DoxGPT [11] - Record engagement was noted with over 650,000 unique prescribers utilizing various digital tools, and AI-optimized program adoption accounted for 40% of bookings [12]

Financial Data and Key Metrics Changes - The company reported revenue of $169 million for Q2 2026, representing a 23% year-on-year growth and a 7% beat from the high end of guidance [6][11] - Adjusted EBITDA margin was 60%, amounting to $101 million, which was 15% above the high end of guidance [6][12] - Free cash flow increased by 37% year-on-year, reaching $91.6 million [13] Business Line Data and Key Metrics Changes - The company achieved an all-time record number of quarterly active subscribers for its Newsfeed, with double-digit growth in articles read [7] - Over 650,000 unique prescribers used the workflow tools in Q2, marking another all-time high [7] - AI tools saw the fastest growth, with quarterly active prescribers up more than 50% from the prior quarter [7] Market Data and Key Metrics Changes - The company finished the quarter with a net revenue retention rate of 118% on a trailing 12-month basis [11] - The number of customers contributing at least $500,000 each in subscription-based revenue increased by approximately 16% year-on-year [11] Company Strategy and Development Direction - The company is focusing on AI-optimized integrated programs, which represented over 40% of bookings in Q2, compared to less than 5% in the same quarter last year [15][39] - The integration of Pathway's medical data set and AI models into DoxGPT is expected to enhance the company's offerings in medical AI [8][60] - The company aims to maintain a 55%+ Adjusted EBITDA margin while investing in AI solutions [17] Management's Comments on Operating Environment and Future Outlook - Management expressed some uncertainty regarding the 2026 budget discussions, indicating a cautious approach to revenue expectations [20][21] - Despite potential headwinds, management remains optimistic about client engagement and the performance of integrated programs [21] - The company expects revenue for Q3 2026 to be in the range of $180 million to $181 million, representing a 7% growth at the midpoint [14] Other Important Information - The company repurchased $21.9 million worth of shares during Q2, with $280 million remaining in the existing repurchase program [13] - The company is excited about the long-term growth opportunities presented by its AI suite [17] Q&A Session Summary Question: Uncertainty around budget discussions - Management indicated that the uncertainty primarily relates to calendar 2026 budgets, which are expected to be finalized soon [20] Question: Future AI opportunities - Management expressed excitement about the potential for AI to add significant value for physicians, with plans to continue expanding AI capabilities [22][23] Question: Budget allocation changes - Management noted that clients are considering potential changes in budget allocations, particularly in light of recent policy changes [28][30] Question: Impact of direct-to-consumer advertising - Management acknowledged that while there are discussions around D2C advertising, it is still early to assess the impact on budgets [29][30] Question: Integrated programs and visibility - Management clarified that integrated offerings represented 40% of upsell sales in Q2, which provides better visibility for future revenue [48][49] Question: Market share and growth - Management stated that the company has been growing at about two times the market growth rate, with a strong competitive position [88][89]

Core Insights - Doximity, Inc. is recognized as a leading healthcare technology stock, utilizing AI-driven tools and strategic acquisitions to enhance its market position [1] - The recent acquisition of Pathway Medical significantly improves Doximity's DoxGPT tool, providing instant access to verified medical data and AI responses [2] - Doximity has introduced Doximity Scribe, an AI tool that automates clinical documentation, thereby reducing administrative workload for clinicians [3] Financial Performance - In the last quarter ending June 30, 2025, Doximity reported a 15% year-over-year revenue increase, reaching $145.9 million, surpassing analyst expectations [4] - The company achieved non-GAAP earnings per share (EPS) of $0.36, indicating strong financial performance [4] - User engagement and product adoption have notably increased, particularly for new AI scribe and workflow tools [4]